Patents by Inventor Nicolas Soldermann

Nicolas Soldermann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250059181
    Abstract: The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I), wherein Y, R1, R2 and m are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.
    Type: Application
    Filed: November 8, 2023
    Publication date: February 20, 2025
    Applicant: Novartis AG
    Inventors: Nigel Graham Cooke, Paulo Fernandes Gomes dos Santos, Nadege Graveleau, Christina Hebach, Klemens Högenauer, Gregory Hollingworth, Alexander Baxter Smith, Nicolas Soldermann, Frank Stowasser, Ross Sinclair Strang, Nicola Tufilli, Anette Von Matt, Romain Wolf, Frédéric Zecri
  • Publication number: 20240382457
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
    Type: Application
    Filed: July 18, 2024
    Publication date: November 21, 2024
    Inventors: Vincent BORDAS, Cara BROCKLEHURST, Patrick CHENE, Pascal FURET, Vito GUAGNANO, Patricia IMBACH-WEESE, Joerg KALLEN, Mickael LE DOUGET, Edwige Liliane Jeanne LORTHIOIS, Joseph MCKENNA, Bahaa SALEM, Tobias SCHMELZLE, Holger SELLNER, Nicolas SOLDERMANN, Markus VOEGTLE, Markus WARTMANN
  • Publication number: 20240382600
    Abstract: The present disclosure relates to a conjugate comprising a YAP/TAZ-TEAD Protein Protein Interaction Inhibitor (PPII) linked to a Ligase Binder via a linker, or a pharmaceutically acceptable salt thereof, as well as methods of using such conjugates.
    Type: Application
    Filed: August 30, 2022
    Publication date: November 21, 2024
    Inventors: Emilie CHAPEAU, Patrick CHENE, Pascal FURET, Laurence KIEFFER, Rainer MACHAUER, Anne PICARD, Tobias SCHMELZLE, Holger SELLNER, Nicolas SOLDERMANN, Markus VOEGTLE, Markus WARTMANN
  • Patent number: 12083101
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
    Type: Grant
    Filed: March 15, 2021
    Date of Patent: September 10, 2024
    Assignee: Novartis AG
    Inventors: Vincent Bordas, Cara Brocklehurst, Patrick Chene, Pascal Furet, Vito Guagnano, Patricia Imbach-Weese, Joerg Kallen, Mickael Le Douget, Edwige Liliane Jeanne Lorthiois, Joseph McKenna, Bahaa Salem, Tobias Schmelzle, Holger Sellner, Nicolas Soldermann, Markus Voegtle, Markus Wartmann
  • Publication number: 20220267318
    Abstract: The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I), wherein Y, R1, R2 and m are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.
    Type: Application
    Filed: August 11, 2021
    Publication date: August 25, 2022
    Applicant: Novartis AG
    Inventors: Nigel Graham Cooke, Paulo Fernandes Gomes Dos Santos, Nadege Graveleau, Christina Hebach, Klemens Hoegenauer, Gregory John Hollingworth, Alexander Baxter Smith, Nicolas Soldermann, Frank Stowasser, Ross Sinclair Strang, Nicola Tufilli, Anette von Matt, Romain Wolf, Frederic Zecri
  • Publication number: 20210299100
    Abstract: The present invention provides a compound of formula (1) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
    Type: Application
    Filed: March 15, 2021
    Publication date: September 30, 2021
    Inventors: Vincent BORDAS, Cara BROCKLEHURST, Patrick CHENE, Zhongbo FEI, Pascal FURET, Vito GUAGNANO, Patricia IMBACH-WEESE, Joerg KALLEN, Mickael LE DOUGET, Jialiang LI, Wei LI, Edwige Liliane Jeanne LORTHIOIS, Joseph McKENNA, Bahaa SALEM, Tobias SCHMELZLE, Holger SELLNER, Nicolas SOLDERMANN, Markus VOEGTLE, Markus WARTMANN
  • Publication number: 20200392132
    Abstract: The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I), wherein Y, R1, R2 and m are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.
    Type: Application
    Filed: June 30, 2020
    Publication date: December 17, 2020
    Applicant: Novartis AG
    Inventors: Nigel Graham Cooke, Paulo Fernandes Gomes Dos Santos, Nadege Graveleau, Christina Hebach, Klemens Hoegenauer, Gregory John Hollingworth, Alexander Baxter Smith, Nicolas Soldermann, Frank Stowasser, Ross Sinclair Strang, Nicola Tufilli, Anette von Matt, Romain Wolf, Frederic Zecri
  • Publication number: 20190218217
    Abstract: The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I), wherein Y, R1, R2 and m are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.
    Type: Application
    Filed: March 28, 2019
    Publication date: July 18, 2019
    Inventors: Nigel Graham Cooke, Paulo Fernandes Gomes Dos Santos, Nadege Graveleau, Christina Hebach, Klemens Hoegenauer, Gregory John Hollingworth, Alexander Baxter Smith, Nicolas Soldermann, Frank Stowasser, Ross Sinclair Strang, Nicola Tufilli, Anette von Matt, Romain Wolf, Frederic Zecri
  • Publication number: 20190040061
    Abstract: The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I), wherein Y, R1, R2 and m are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.
    Type: Application
    Filed: October 17, 2018
    Publication date: February 7, 2019
    Inventors: Nigel Graham Cooke, Paulo Fernandes Gomes Dos Santos, Nadege Graveleau, Christina Hebach, Klemens Hoegenauer, Gregory John Hollingworth, Alexander Baxter Smith, Nicolas Soldermann, Frank Stowasser, Ross Sinclair Strang, Nicola Tufilli, Anette von Matt, Romain Wolf, Frederic Zecri
  • Publication number: 20180265509
    Abstract: The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I), wherein Y, R1, R2 and m are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.
    Type: Application
    Filed: May 30, 2018
    Publication date: September 20, 2018
    Inventors: Nigel Graham Cooke, Paulo Fernandes Gomes Dos Santos, Nadege Graveleau, Christina Hebach, Klemens Hoegenauer, Gregory John Hollingworth, Alexander Baxter Smith, Nicolas Soldermann, Frank Stowasser, Ross Sinclair Strang, Nicola Tufilli, Anette von Matt, Romain Wolf, Frederic Zecri
  • Patent number: 9949979
    Abstract: The invention relates to new uses of PI3K inhibitors, wherein said inhibitors have an inhibitory action on the PI3K isoform delta for the treatment of immunopathology in a subject suffering from a disease or disorder selected from malaria, leishmaniasis, trypanosomiasis, toxoplasmosis and/or neurocysticercosis, via functional inhibition of TLR9 of the infected subject.
    Type: Grant
    Filed: December 14, 2012
    Date of Patent: April 24, 2018
    Assignee: Novartis AG
    Inventors: Nigel Graham Cooke, Paulo Antonio Fernandes Gomes Dos Santos, Pascal Furet, Christina Hebach, Klemens Hoegenauer, Gregory Hollingworth, Christoph Kalis, Ian Lewis, Alexander Baxter Smith, Nicolas Soldermann, Frederic Stauffer, Ross Strang, Frank Stowasser, Nicola Tuffilli, Anette Von Matt, Romain Wolf, Frederic Zecri
  • Patent number: 9840498
    Abstract: Provided are substituted quinazolin-4-one compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, wherein R1, R2, R3, R5, R6 and L are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the class I PI3K kinases.
    Type: Grant
    Filed: July 24, 2014
    Date of Patent: December 12, 2017
    Assignee: Novartis AG
    Inventors: Zhenxing Du, Samuel Hintermann, Konstanze Hurth, Sébastien Jacquier, Hansjoerg Lehmann, Henrik Moebitz, Nicolas Soldermann, Aleksandar Stojanovic
  • Publication number: 20170267678
    Abstract: The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I), wherein Y, R1, R2 and m are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.
    Type: Application
    Filed: June 5, 2017
    Publication date: September 21, 2017
    Applicant: Novartis AG
    Inventors: Nigel Graham COOKE, Paulo Fernandes Gomes Dos Santos, Nadege GRAVELEAU, Christina HEBACH, Klemens HOEGENAUER, Gregory John HOLLINGWORTH, Alexander Baxter SMITH, Nicolas SOLDERMANN, Frank STOWASSER, Ross Sinclair STRANG, Nicola TUFILLI, Anette von MATT, Romain WOLF, Frederic ZECRI
  • Patent number: 9763952
    Abstract: The invention relates to dihydro-benzo-oxazine and dihydro-pyrido-oxazine compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, wherein Y, V, W, U, Q, R1, R5, R7 and R30 are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: September 19, 2017
    Assignee: NOVARTIS AG
    Inventors: Giorgio Caravatti, Sylvie Chamoin, Pascal Furet, Klemens Hogenauer, Konstanze Hurth, Karen Kammertoens, Ian Lewis, Henrik Moebitz, Alexander Baxter Smith, Nicolas Soldermann, Romain Wolf, Frederic Zecri
  • Patent number: 9539260
    Abstract: The invention relates to dihydro-benzo-oxazine and dihydro-pyrido-oxazine compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, wherein Y, V, W, U, Q, R1, R5, R7 and R30 are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: January 10, 2017
    Assignee: NOVARTIS AG
    Inventors: Giorgio Caravatti, Sylvie Chamoin, Pascal Furet, Klemens Hogenauer, Konstanze Hurth, Karen Kammertoens, Ian Lewis, Henrik Moebitz, Alexander Baxter Smith, Nicolas Soldermann, Romain Wolf, Frederic Zecri
  • Patent number: 9499536
    Abstract: The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I), wherein Y, R1, R2 and m are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.
    Type: Grant
    Filed: January 9, 2014
    Date of Patent: November 22, 2016
    Assignee: Novartis AG
    Inventors: Nigel Graham Cooke, Frédèric Zecri, Nicolas Soldermann, Romain Wolf, Christina Hebach, Klemens Hoegenauer, Gregory John Hollingworth, Anette Von Matt, Ross Sinclair Strang, Alexander Baxter Smith, Paulo Fernandes Gomes Dos Santos, Nadege Graveleau, Frank Stowasser, Nicola Tufilli
  • Publication number: 20160168131
    Abstract: Provided are substituted quinazolin-4-one compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, wherein R1, R2, R3, R5, R6 and L are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the class I PI3K kinases.
    Type: Application
    Filed: July 24, 2014
    Publication date: June 16, 2016
    Applicant: NOVARTIS AG
    Inventors: Zhenxing DU, Samuel HINTERMANN, Konstanze HURTH, Sébastien JACQUIER, Hansjoerg LEHMANN, Henrik MOEBITZ, Nicolas SOLDERMANN, Aleksandar STOJANOVIC
  • Publication number: 20160106753
    Abstract: The invention relates to dihydro-benzo-oxazine and dihydro-pyrido-oxazine compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, wherein Y, V, W, U, Q, R1, R5, R7 and R30 are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.
    Type: Application
    Filed: December 21, 2015
    Publication date: April 21, 2016
    Applicant: Novartis AG
    Inventors: Giorgio CARAVATTI, Sylvie CHAMOIN, Pascal FURET, Klemens HOGENAUER, Konstanze HURTH, Christoph KALIS, Karen KAMMERTOENS, Ian LEWIS, Henrik MOEBITZ, Alexander Baxter SMITH, Nicolas SOLDERMANN, Romain WOLF, Frederic ZECRI
  • Publication number: 20150342951
    Abstract: The invention relates to new uses of PI3K inhibitors, wherein said inhibitors have an inhibitory action on the PI3K isoform delta for the treatment of immunopathology in a subject suffering from a disease or disorder selected from malaria, leishmaniasis, trypanosomiasis, toxoplasmosis and/or neurocysticercosis, via functional inhibition of TLR9 of the infected subject.
    Type: Application
    Filed: December 14, 2012
    Publication date: December 3, 2015
    Applicant: NOVARTIS AG
    Inventors: Nigel Graham COOKE, Paulo Antonio FERNANDES GOMES DOS SANTOS, Pascal FURET, Christina HEBACH, Klemens HOGENAUER, Gregory HOLLINGWORTH, Christoph KALIS, Ian LEWIS, Alexander Baxter SMITH, Nicolas SOLDERMANN, Frederic STAUFFER, Ross STRANG, Frank STOWASSER, Nicola TUFFILLI, Anette VON MATT, Romain WOLF, Frederic ZECRI
  • Publication number: 20150148377
    Abstract: The invention relates to quinoline compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, wherein Y, W, U, Q, R1, R5 R7 and R30 are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.
    Type: Application
    Filed: December 20, 2012
    Publication date: May 28, 2015
    Applicant: NOVARTIS AG
    Inventors: Klemens Hogenauer, Konstanze Hurth, Christoph Kalis, Henrik Moebitz, Nicolas Soldermann, Frederic Zecri